| Literature DB >> 31754357 |
Samira Tajik1, Shahin Najar-Peerayeh1, Bita Bakhshi1, Reza Golmohammadi2.
Abstract
BACKGROUND &Entities:
Keywords: Burn; MRSA; Patients; SCCmec
Year: 2019 PMID: 31754357 PMCID: PMC6824769 DOI: 10.30699/ijp.2019.94189.1917
Source DB: PubMed Journal: Iran J Pathol ISSN: 1735-5303
The list of primers sequences for mecA, pvl, tsst-1, hla-α, and psmα genes detection, SCCmec and agr typing and PCR products length
| Ref | Size (bp) | Sequence (5ʹ→3ʹ) | Primer | |
|---|---|---|---|---|
| ( | 146 | F: GTGAAGATATACCAAGTGATT |
|
|
| ( | 613 | F: GCTTTAAAGAGTGTCGTTACAGG | SCC | SCC |
| 398 | F: CGTTGAAGATGATGAAGCG | SCC | ||
| 280 | F: CCATATTGTGTACGATGCG | SCC | ||
| 776 | F: GCCTTATTCGAAGAAACCG | SCC | ||
| 493 | F: TCTGGAATTACTTCAGCTGC | SCC | ||
| 200 | F: ACAATATTTGTATTATCGGAGAGC | SCC | ||
| 881 | F: CTCAAAATACGGACCCCAATACA | SCC | ||
| 325 | F: GAACATTGTTACTTAAATGAGCG | SCC | ||
| ( | - | ATGCACATGGTGCACATGC | panF |
|
| 440 | GTCACAAGTACTATAAGCTGCGAT |
| ||
| 572 | GTATTACTAATTGAAAAGTGCCATAGC |
| ||
| 406 | CTGTTGAAAAAGTCAACTAAAAGCTC |
| ||
| 588 | CGATAATGCCGTAATAC CCG |
| ||
| ( | 502 | F: GGAAACATTTATTCTGGCTATAC |
| Virulence genes typing |
| 398 | F: TTATCGTAAGCCCTTTGTTG |
| ||
| 744 | F: CGGTACTACAGATATTGGAAGC |
| ||
| ( | 176 | F: TATCAAAAGCTTAATCGAACAATTC |
|
Antibiotic resistance of MSSA and MRSA isolated from burn patient
| Antibiotics | MSSA (n=18) | MRSA (n=13) | Total (n=31) |
|---|---|---|---|
| cefoxitin | 0 | 13 (100%) | 13 (41.9%) |
| erythromycin | 6 (33.3%) | 9 (69.2%) | 15(48.4%) |
| tetracycline | 3 (16.7%) | 8 (61.5%) | 11(35.5%) |
| ciprofloxacin | 2 (11.1%) | 9 (69.2%) | 11(35.5%) |
| gentamicin | 1 (5.5%) | 9 (69.2%) | 10(32.3%) |
| clindamycin | 2 (11.1%) | 7 (53.8%) | 9(29.0%) |
| rifampin | 1 (5.5%) | 5 (38.5%) | 6(19.4%) |
| trimethoprim-sulfamethoxazole | 0 | 4 (30.8%) | 4(12.9%) |
| Linezolid | 0 | 0 | 0 |
The mecA, pvl, tsst-1, hla-α, and psmα genes detection, and SCCmec and agr typing result (n=31)
|
|
|
|
|
| SCC |
| gene | ||
|---|---|---|---|---|---|---|---|---|---|
|
| 21(67.7%) | 4(12.9%) | 3(9.7%) | 14(45.1%) | type 1 | 9(69.2%) | type3 | 13(41.9%) |
|
| 1(3.2%) | type 3 | 1(7.7%) | type2 | ||||||
| 6(19.4%) | type 4 | 3(23.1%) | Not typeable | ||||||
| 10(32.3%) | Not typeable | ||||||||
|
| 10(32.3%) | 27(87.1%) | 28(90.3) | 0(0%) | 18 | 18(58.1%) |
| ||
Figure1PFGE analysis of CA-MRSA in current study